CTLA4 and hypophysitis: The first reported case of immune checkpoint inhibitor (ICI)-induced hypophysitis is from the National Cancer Institute in 2003, in a patient with metastatic melanoma managed with ipilimumab, the monoclonal antibody for CTLA4 [10].